Dallas、TXにおける胃癌の臨床試験
Dallasとその周辺地域（約30マイル以内）の拠点で、胃癌に関する19件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- UT Southwestern, Dallas
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
被験者募集中第3相
- Baylor Scott & White Health, Dallas
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
被験者募集中第1/2相
- Baylor, Scott and White Research Institute, Dallas
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- Texas Oncology - DFW (Sammons CC), Dallas
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
被験者募集中第1相
- Texas Oncology - DFW (Sammons CC), Dallas
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
被験者募集中第3相
- Research Site, Dallas
- Research Site, Dallas
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
被験者募集中第1/2相
- Mary Crowley Cancer Research, Dallas
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- Mary Crowley Cancer Research, Dallas
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
被験者募集中第3相
- UT Southwestern Medical Center, Dallas
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Texas Oncology, Dallas
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
被験者募集中第1相
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- 他2件
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
被験者募集中第2相
- Texas Oncology - DFW, Dallas
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
被験者募集中第2相
- Texas Oncology Dallas Methodist, Dallas
- Texas Oncology Dallas Medical City, Dallas
- Texas Oncology Dallas Presbyterian, Dallas
- 他2件
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
被験者募集中第1/2相
- University of Texas Southwestern Medical Center, Dallas
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
被験者募集中第1相
- Baylor University Medical Center, Dallas
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
被験者募集中第1相
- NEXT Dallas, Dallas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
被験者募集中第1相
- Dren Investigational Site, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Dallas
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
被験者募集中第1/2相
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
他の都市における胃癌の試験
- Houston, TX42件の研究
- Boston, MA32件の研究
- New York City, NY31件の研究
- Nashville, TN28件の研究
- Baldwin Park, CA22件の研究
- Los Angeles, CA22件の研究
- Arlington, VA20件の研究
- San Antonio, TX19件の研究
- St. Louis, MO18件の研究
- Grand Rapids, MI18件の研究
- Washington, DC16件の研究
- Chicago, IL16件の研究
Dallasにおける他の研究
- 乳がん55件の研究
- 非小細胞肺癌52件の研究
- 転移性癌42件の研究
- 心不全42件の研究
- がん（全種類）37件の研究
- 前立腺がん36件の研究
- 大腸癌33件の研究
- 肥満症30件の研究
- 卵巣がん28件の研究
- 肺がん27件の研究
- 膀胱癌27件の研究
- 子宮内膜がん24件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。